B+
Bull case
20%
Probability
Target price
$3.10
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
TXMD
TherapeuticsMDDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$1.80
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.90
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-13
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+42.9
Score
AI commentary
Post-earnings tone is mixed and monitoring-oriented: cash increased from $8.4 million at March 31 to $9.2 million at June 30, while license revenue and net income declined year over year. No reliable consensus surprise, analyst revision, target change, or detailed post-print market-reaction evidence is available in the packet; social coverage is absent. The evidence supports a cautious, low-conviction stance rather than a bullish catalyst call.
RankAlpha Sentiment Codex - 2026-08-13
Open post-earnings memoEvidence flagged
Coverage is limited for this name, so the memo relies on a thinner evidence base.; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-08-11eventQ2 2026 results were mixedMedium impact
TherapeuticsMD reported $869 thousand of Q2 license revenue versus $952 thousand a year earlier, net income from continuing operations of $164 thousand versus $545 thousand, operating expenses of $1.7 million, and cash of $9.2 million. Strategic-alternative exploration continues, but there is no timetable or transaction assurance [#SEC-8K-2026-08-11].
2026-08-31catalystRoyalty-revenue and post-earnings risk remain near-term focusHigh impact
The weaker year-over-year license revenue and limited forward disclosure leave the stock vulnerable to renewed selling if royalty receipts soften or liquidity concerns re-emerge.
2027-08-13catalystStrategic-alternative review is the only identified long-horizon optionalityHigh impact
Upside depends on a credible strategic transaction or evidence that licensee sales can stabilize or grow royalty receipts. Management provides no timetable and explicitly gives no assurance of success [#SEC-8K-2026-08-11]. No distinct long-horizon development, partnership, or financing catalyst is established in the available evidence.
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-13 • Updated nightlySource: Internal modelMethodology